Rua Bioscience Limited — Capital/Financing Update 2024

Dec 12, 2024

MARKET UPDATE

==> picture [132 x 77] intentionally omitted <==

FOR PUBLIC RELEASE

NZX Limited Wellington

12 December 2024

Sales continue to significantly increase

As we approach the half-year mark, we can report strong momentum in our sales performance across our key markets. Our revenue is forecast to exceed $600,000 (unaudited) for the six-month period, and we expect to have unaudited sales of approximately $400,000 for the October to December quarter. This will be approximately 80% growth quarter-on-quarter.

This significant growth reflects our increased presence in both domestic and international markets.

==> picture [432 x 253] intentionally omitted <==

----- Start of picture text ----- 40022345ACTUAL ACTUAL FORECASTQ4 FY24 Q1 FY25 Q2 FY25Apr - Jun Jul - Sep Oct - Dec----- End of picture text -----

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com

Germany

We continue to expand our product portfolio in this market, with the launch of a new product in December. This reinforces our position in Europe’s largest medicinal cannabis market, with increased sales expected over the coming months.

Australia

Our sales in this large but competitive market are steadily growing, with our distribution channels and product portfolio now firmly established. We continue to foster key partnerships and remain committed to growing sales in this key market.

New Zealand

Locally, we have released an additional dried flower product now available to patients. Sales month on month continue to increase, with highest sales reported for the month of December following from the release of this new product. In addition, we have new products currently being assessed by the NZ Ministry of Health.

United Kingdom

We have successfully launched three oil products in December and these products are now available to patients and prescribers via our distribution partner, Target Health. Over the coming months we will continue to be build relationships with key clinics to build awareness of Rua in this key market.

Delivering on Strategy

These achievements highlight our focus delivering our differentiated strategy with efficiency and focus. By leveraging our expertise in genetic development, and international distribution, we are creating a scalable high-value intergenerational company.

ENDS

The person who authorised this announcement:

Paul Naske Chief Executive Officer paul.naske@ruabio.com +64 21 445154

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com